Last 7,370 KRW
Change Today -100.00 / -1.34%
Volume 70.2K
086890 On Other Exchanges
As of 1:13 AM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

isu abxis co ltd (086890) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/18/14 - 14,000
52 Week Low
12/19/13 - 5,600
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ISU ABXIS CO LTD (086890)

Related News

No related news articles were found.

isu abxis co ltd (086890) Related Businessweek News

No Related Businessweek News Found

isu abxis co ltd (086890) Details

ISU ABXIS Co., Ltd. is engaged in pharmaceutical and diagnosis businesses in South Korea and internationally. The company operates in three divisions: Therapeutic Antibody Business, Medical Service Business, and Others. It offers Clotinab abciximab, a monoclonal therapeutic antibody used as a supplement for heparine and aspirin to prevent ischemic heart complications of high risk group of patients during the operation of coronary angioplasty. The company also provides ATP-CRA, an anti-cancer medicine reactive test to measure the content of ATP retained by living cells; and genetic testing service for analyzing and providing measured genes for various diseases. The company sells its products to pharmaceutical companies, medicine wholesalers, hospitals, and retailers through wholesalers, pharmaceutical companies, and medical suppliers. It has a strategic collaboration with Catalyst Biosciences, Inc. The company is headquartered in Seoul, South Korea.

isu abxis co ltd (086890) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

isu abxis co ltd (086890) Key Developments

ISU ABXIS Co., Ltd., Annual General Meeting, Mar 21, 2014

ISU ABXIS Co., Ltd., Annual General Meeting, Mar 21, 2014., at 09:00 Korea Standard Time. Location: Pan-gyo is 712 Bundang Great beongil 22 C global R & D center.

Catalyst Biosciences, Inc. and Isu Abxis Form Strategic Collaboration

Catalyst Biosciences, Inc. and Isu Abxis announced the companies have formed a strategic collaboration to develop Catalyst's next-generation Factor IX development candidate FIX-NG (CB 2679d) for the prevention and treatment of bleeding in hemophilia B patients. The collaboration will advance FIX-NG through IND-enabling preclinical studies, manufacturing and the completion of Phase 1 clinical studies designed to establish proof-of-mechanism for the molecule in hemophilia B patients. Under the terms of the collaboration, Isu Abxis will use its biologics manufacturing and development expertise to advance FIX-NG through preclinical and Phase 1 studies and Catalyst and Isu will collaborate and share in profits on the development and commercialization of FIX-NG worldwide. Isu will pay Catalyst an upfront licensing fee and milestone payments through the end of the Phase 1 clinical trial and holds an option to exclusively commercialize FIX-NG in Korea. Catalyst retains development and commercial ownership rights of the program outside of Korea.

ISU ABXIS Co., Ltd., Annual General Meeting, Mar 22, 2013

ISU ABXIS Co., Ltd., Annual General Meeting, Mar 22, 2013., at 09:00 Korea Standard Time. Location: Bundang sampyeongdong 696-1 global R & D center C. Agenda: To approve statement of financial position, income statement, statement of retained earnings (deficit) on disposal of financial statements ended December 31, 2012; to approve election of director of managing director and directors' remuneration limit; and to approve other references concerning investment decisions.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
086890:KS 7,370.00 KRW -100.00

086890 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 086890.
View Industry Companies

Industry Analysis


Industry Average

Valuation 086890 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.7x
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISU ABXIS CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at